These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38118388)

  • 1. Safety and efficacy of fixed versus variable-dose prothrombin complex concentrate for emergent reversal of vitamin K antagonists: A systematic review and meta-analysis.
    Condeni MS; Weant KA; Neyens RR; Eriksson EA; Miano TA
    Am J Emerg Med; 2024 Mar; 77():91-105. PubMed ID: 38118388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed- Versus Variable-Dose Prothrombin Complex Concentrate for the Emergent Reversal of Vitamin K Antagonists: A Systematic Review and Meta-Analysis.
    Alwakeal A; Maas MB; Naidech AM; Jahromi BS; Potts MB
    Crit Care Med; 2024 May; 52(5):811-820. PubMed ID: 38353592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective Evaluation of a Fixed-Dose 4-Factor Prothrombin Complex Concentrate Protocol for Urgent Vitamin K Antagonist Reversal.
    Bitonti MT; Rumbarger RL; Absher RK; Curran LM
    J Emerg Med; 2020 Feb; 58(2):324-329. PubMed ID: 31787372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight-Based Dosing Versus a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate in Obese Patients Requiring Vitamin K Antagonist Reversal.
    Elsamadisi P; Cepeda MAG; Yankama T; Wong A; Tran Q; Eche IM
    Am J Cardiovasc Drugs; 2021 May; 21(3):355-361. PubMed ID: 33150496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
    Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
    Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
    Brekelmans MPA; Ginkel KV; Daams JG; Hutten BA; Middeldorp S; Coppens M
    J Thromb Thrombolysis; 2017 Jul; 44(1):118-129. PubMed ID: 28540468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of the Fixed-Dose Versus Variable-Dose of 4-PCC for Vitamin K Antagonist Reversal: A Comprehensive Systematic Review and Meta-Analysis.
    Mohammadi K; Yaribash S; Sani MA; Talasaz AH
    Cardiovasc Drugs Ther; 2022 Jun; 36(3):533-546. PubMed ID: 33864534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial.
    Goldstein JN; Refaai MA; Milling TJ; Lewis B; Goldberg-Alberts R; Hug BA; Sarode R
    Lancet; 2015 May; 385(9982):2077-87. PubMed ID: 25728933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fixed-Dose Four-Factor Prothrombin Complex Concentrate for Vitamin K Antagonist Reversal: Does One Dose Fit All?
    Schwebach AA; Waybright RA; Johnson TJ
    Pharmacotherapy; 2019 May; 39(5):599-608. PubMed ID: 30892733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate for Bleeding Complications of Vitamin K Antagonists-The PROPER3 Randomized Clinical Trial.
    Abdoellakhan RA; Khorsand N; Ter Avest E; Lameijer H; Faber LM; Ypma PF; Nieuwenhuizen L; Veeger NJGM; Meijer K
    Ann Emerg Med; 2022 Jan; 79(1):20-30. PubMed ID: 34535300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal following a fixed-dose strategy.
    Sobrino Jiménez C; Romero-Garrido JA; García-Martín Á; Quintana-Díaz M; Jiménez-Vicente C; González-Del Valle L; Herrero Ambrosio A; Benedí-González J
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e66-e71. PubMed ID: 32591479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a Fixed-Dose Regimen of 4-Factor Prothrombin Complex Concentrate for Warfarin Reversal.
    McMahon C; Halfpap J; Zhao Q; Bienvenida A; Rose AE
    Ann Pharmacother; 2021 Oct; 55(10):1230-1235. PubMed ID: 33522256
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3-Factor versus 4-Factor Prothrombin Complex Concentrates for the Reversal of Vitamin K Antagonist-Associated Coagulopathy: A Systematic Review and Meta-analysis.
    Puchstein D; Kork F; Schöchl H; Rayatdoost F; Grottke O
    Thromb Haemost; 2023 Jan; 123(1):40-53. PubMed ID: 36626899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.
    Desmettre T; Dehours E; Samama CM; Jhundoo S; Pujeau F; Guillaudin C; Hecquart C; Clerson P; Crave JC; Jaussaud R
    Crit Care; 2012 Oct; 16(5):R185. PubMed ID: 23036234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fixed- versus variable-dose prothrombin complex concentrate protocol for vitamin K antagonist reversal.
    Bizzell AC; Mousavi MK; Yin E
    Int J Hematol; 2021 Sep; 114(3):334-341. PubMed ID: 34191234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
    Sin JH; Berger K; Lesch CA
    J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
    Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
    Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed Versus Variable Dosing of Prothrombin Complex Concentrate in Vitamin K Antagonist-Related Intracranial Hemorrhage: A Retrospective Analysis.
    Abdoellakhan RA; Miah IP; Khorsand N; Meijer K; Jellema K
    Neurocrit Care; 2017 Feb; 26(1):64-69. PubMed ID: 27052728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of four-factor prothrombin complex concentrate fixed, weight-based dosing for reversal of warfarin anticoagulation.
    Endres K; St Bernard R; Chin-Yee I; Hsia C; Lazo-Langner A
    Hematology; 2020 Dec; 25(1):489-493. PubMed ID: 33317427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study.
    Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN
    Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.